Intracavitary Chemotherapy after kidney-Sparing Therapy for Upper Tract Urothelial Carcinoma: A Meta-Analysis.
Urology journal./Urology jornal. · 26.12.2023 · 20 (6) · 369-378
DOI: 10.22037/uj.v20i.7530 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Urology journal./Urology jornal., erschienen am 26.12.2023. Verfasst von Hang Zhou und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, General Hospital of Tianjin Medical University, Tianjin, 300052, China. zhouhang0831@163.com. Hauptthemen laut MEDLINE: Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Kidney Neoplasms, Ureteral Neoplasms.
Themen: Onkologische Pflege
Abstract (Originalsprache)
PURPOSE: Intracavitary chemotherapy is one of the current treatment options for kidney-sparing treatment of upper tract urothelial carcinoma (UTUC). The purpose of this meta-analysis was to assess the efficacy and safety of intracavitary perfusion. METHODS: We carefully selected publications for study from four databases (Embase, PubMed, Web of Science, and Scopus) up to January 2023. The R 4.0.4 software was used to calculate the pooled ratio and its 95% confidence intervals (95% CIs). The I2 score was used to test heterogeneity, and the funnel plot was used to estimate the publication bias. RESULTS: Thirty-four studies with a total of 788 patients were included in this study. The overall survival at a median follow-up of 26.3 months was 87.2% (95% CI 0.80-0.93). The cancer-specific survival at a median follow-up of 30 months was 94.1% (95% CI 0.89-0.98). At a median follow-up of 30 months, the recurrence rate of UTUC was 27.5% (95% CI 0.21-0.34). By subgroup analysis, we found that the recurrence rate in patients with T1 / Ta stage was 35.1% and CIS stage 29.0%. The recurrence rates of BCG, Mitomycin C, and Mitomycin Gel (UGN101) were 31.2%, 41.3% and 12.9%, respectively. The recurrence rates for anterograde and retrograde perfusion were 28.5% and 21.8%, respectively. CONCLUSION: With the advent of new drugs, including UGN101, patients with UTUC have a better prognosis. Therefore, kidney preservation therapy for patients with UTUC would be promising.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Urology, General Hospital of Tianjin Medical University, Tianjin, 300052, China. zhouhang0831@163.com.
- Department of Urology, General Hospital of Tianjin Medical University, Tianjin, 300052, China. panyang361@163.com.
- Department of Urology, General Hospital of Tianjin Medical University, Tianjin, 300052, China. x18670053557mm@163.com.
- Department of Urology, General Hospital of Tianjin Medical University, Tianjin, 300052, China. wangshangren89@tmu.edu.cn.
- Department of Urology, General Hospital of Tianjin Medical University, Tianjin, 300052, China. 18333666683@163.com.
- Department of Urology, General Hospital of Tianjin Medical University, Tianjin, 300052, China. xiaoqiangliu1@163.com.
Zitieren
APA
Zhou, H., Pan, Y., Xu, M., Wang, S., Li, Y., & Liu, X. (2023). Intracavitary Chemotherapy after kidney-Sparing Therapy for Upper Tract Urothelial Carcinoma: A Meta-Analysis. Urology journal./Urology jornal., 20(6), 369-378. https://doi.org/10.22037/uj.v20i.7530
Vancouver
Zhou H, Pan Y, Xu M, Wang S, Li Y, Liu X. Intracavitary Chemotherapy after kidney-Sparing Therapy for Upper Tract Urothelial Carcinoma: A Meta-Analysis. Urology journal./Urology jornal.. 2023;20(6):369-378. doi:10.22037/uj.v20i.7530
BibTeX
@article{Zhou2023,
author = {Zhou, Hang and Pan, Yang and Xu, Mingming and Wang, Shangren and Li, Yuezheng and Liu, Xiaoqiang},
title = {Intracavitary Chemotherapy after kidney-Sparing Therapy for Upper Tract Urothelial Carcinoma: A Meta-Analysis},
journal = {Urology journal./Urology jornal.},
year = {2023},
volume = {20},
number = {6},
pages = {369--378},
doi = {10.22037/uj.v20i.7530}
}
EUVIMED